Latest News

• Bal Pharma Limited is seeking shareholder approval via postal ballot for the appointment of Mr. Ravindra Kumar Kothari (DIN # 03418320) as a Non-Independent and Non-Executive Director.
• The e-voting period will commence on 2 July 2025 at 9:00 A.M. IST and conclude on 31 July 2025 at 5:00 P.M. IST.
• The results of the postal ballot will be announced on or before 18 August 2025 and will be available on the company's website, www.balpharma.com, and the NSDL website.
• Mr. Kothari was initially appointed as an Additional Director effective from 5 May 2025.
• The resolution proposes his appointment as a Director for a term of 5 consecutive years, up to 1 August 2030, with his office being liable to retire by rotation.
• Mr. Kothari is a commerce graduate with 12 years of experience in the Pharma industry and an overall experience of 45 years. He also holds directorships in Bal Research Foundation, Lifezen Healthcare Private Limited, and is a Designated Partner in Balance Clinics LLP.

• Bal Pharma Limited informed shareholders holding shares in physical form to furnish their KYC details to the Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited.
• This is pursuant to SEBI regulations requiring listed companies to record PAN, address with PIN code, mobile number, bank account details, and specimen signature of holders of physical securities.
• Shareholders are requested to register their email ID to avail online services and nomination facility.
• Dividends/interest will be paid electronically from April 1, 2024, only upon furnishing the required details.
• Shareholders can submit KYC details through in-person verification, hard copy submission, or with e-sign.

Bal Pharma Limited has announced the newspaper publication of its abridged Unaudited Standalone and Consolidated financial results for the quarter and financial year ended 31 March 2025. These results, which were approved by the Board of Directors on 29 May 2025, were published in Financial Express (English) and Sanjay vani (Kannada) on 31 May 2025.

Key financial highlights (figures in rupees, Lakhs, or Crore where applicable):

• Total Income from operations (Net):
  • For the quarter ended 31 March 2025: ₹70.49 crore (₹7048.96 Lakhs)
  • For the quarter ended 31 March 2024: ₹73.06 crore (₹7306.33 Lakhs)
  • For the financial year ended 31 March 2025: ₹279.71 crore (₹27971.46 Lakhs)
  • For the financial year ended 31 March 2024: ₹282.50 crore (₹28249.71 Lakhs)
• Net Profit/(Loss) for the period (after tax):
  • For the quarter ended 31 March 2025: Loss of ₹0.07 crore (₹7.33 Lakhs)
  • For the quarter ended 31 March 2024: Loss of ₹0.03 crore (₹2.97 Lakhs)
  • For the financial year ended 31 March 2025: Loss of ₹1.42 crore (₹142.49 Lakhs)
  • For the financial year ended 31 March 2024: Loss of ₹0.15 crore (₹15.22 Lakhs)
• Earnings Per Share (EPS) (Basic & Diluted):
  • For the quarter ended 31 March 2025: (₹0.05)
  • For the quarter ended 31 March 2024: (₹0.02)
  • For the financial year ended 31 March 2025: (₹0.98)
  • For the financial year ended 31 March 2024: (₹0.10)

The company submitted these newspaper advertisements to the exchanges in compliance with Regulation 47 of SEBI (LODR) Regulations, 2015.

Bal Pharma Limited announced that the Hon'ble National Company Law Tribunal (NCLT), Bangalore Bench, pronounced an order on 26 Mar 25 allowing the Scheme of merger of Golden Drugs Pvt Ltd, a wholly-owned subsidiary, with Bal Pharma Limited. The order was uploaded on the NCLT website on the evening of 27 Mar 25.

Key details of the scheme:

• The scheme is pursuant to Sections 230 and 232 of the Companies Act, 2013.
• The appointed date for the Scheme is 1 Apr 23 (changed from the original date of 1 Apr 21 as per NCLT direction).
• The NCLT order mandates Bal Pharma to deposit ₹75,000 with the Pay & Accounts Officer, Chennai, for the Regional Director, and ₹25,000 in favor of The Prime Minister’s National Relief Fund, within four weeks of receiving the certified order copy.
• Bal Pharma is directed to comply with Section 170A of the Income Tax Act, 1961 within the stipulated time.
• The scheme is binding on all shareholders and creditors of both companies.
• The NCLT clarified that the order should not be construed as an exemption from any stamp duty, taxes, or other charges.

The NCLT considered reports from the Regional Director (RD), Registrar of Companies (ROC), Income Tax Department (IT), Official Liquidator (OL), and Reserve Bank of India (RBI), along with replies from the petitioner companies. Several observations were raised by these authorities, including:

• The RD/ROC initially noted discrepancies in the appointed date and capital structure, and non-compliance with Section 89/90 of the Companies Act, 2013. They also requested NOCs from SEBI, BSE, RBI, and other regulatory bodies.
• The IT Department noted pending penalties and tax demands, including demands for assessment years 2008-09 (₹4.88 lakhs and ₹6.01 lakhs), 2009-10 (₹78,767), 2017-18 (₹85.10 lakhs and ₹20,000), 2018-19 (₹1.47 crores), 2019-20 (₹60.55 lakhs), and 2022-23 (₹13.31 lakhs).
• The OL raised concerns about the appointed date, secured creditor approval, related party transactions, and employee retrenchment.
• The RBI highlighted outstanding shipping bills (₹80.57 crores), inward remittance messages (₹117.64 crores), bills of entry (₹106.89 crores), and outward remittances messages (₹85.84 crores).

Bal Pharma has addressed these observations in its reply affidavits, undertaking to comply with applicable laws and regulations.